- Home
- CLRB vs AMBO Comparison
CLRB vs AMBO Comparison
Compare CLRB & AMBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- AMBO
- Stock Information
- Founded
- CLRB 2002
- AMBO 2000
- Country
- CLRB United States
- AMBO United States
- Employees
- CLRB N/A
- AMBO N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- AMBO Other Consumer Services
- Sector
- CLRB Health Care
- AMBO Real Estate
- Exchange
- CLRB Nasdaq
- AMBO Nasdaq
- Market Cap
- CLRB 12.8M
- AMBO 12.7M
- IPO Year
- CLRB N/A
- AMBO 2010
- Fundamental
- Price
- CLRB $3.36
- AMBO $3.77
- Analyst Decision
- CLRB Hold
- AMBO
- Analyst Count
- CLRB 2
- AMBO 0
- Target Price
- CLRB N/A
- AMBO N/A
- AVG Volume (30 Days)
- CLRB 321.2K
- AMBO 570.2K
- Earning Date
- CLRB 10-31-2025
- AMBO 08-05-2025
- Dividend Yield
- CLRB N/A
- AMBO N/A
- EPS Growth
- CLRB N/A
- AMBO N/A
- EPS
- CLRB N/A
- AMBO 0.69
- Revenue
- CLRB N/A
- AMBO $9,699,000.00
- Revenue This Year
- CLRB N/A
- AMBO N/A
- Revenue Next Year
- CLRB N/A
- AMBO N/A
- P/E Ratio
- CLRB N/A
- AMBO $5.59
- Revenue Growth
- CLRB N/A
- AMBO 23.73
- 52 Week Low
- CLRB $3.17
- AMBO $1.25
- 52 Week High
- CLRB $66.00
- AMBO $6.75
- Technical
- Relative Strength Index (RSI)
- CLRB 32.40
- AMBO 44.94
- Support Level
- CLRB $3.70
- AMBO $3.70
- Resistance Level
- CLRB $4.10
- AMBO $4.44
- Average True Range (ATR)
- CLRB 0.32
- AMBO 0.51
- MACD
- CLRB -0.08
- AMBO -0.11
- Stochastic Oscillator
- CLRB 9.69
- AMBO 18.63
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.